Arjan Bredenoord, UEG Week 2022: Analysis of the LIBERTY-EoE-TREET study of dupilumab in eosinophilic esophagitis

LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET study, looking at the efficacy of dupilumab in patients with EoE with and without prior steroid use.

The abstract entitled ‘DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE’ (Abstract no: OP076) was presented at UEG Week, October 8 – 11, 2022.

Questions

1. Could you tell us a little about eosinophilic esophagitis (EoE) and the unmet needs in its treatment? (0:22)
2. What did the LIBERTY-EoE-TREET study teach us about the efficacy and safety of dupilumab in this treatment setting? (0:53)
3. What was the objective of this analysis of the LIBERTY-EoE-TREET study? (1:40)
4. What were the findings of the study in patients with and without prior steroid use? (2:07)
5. What will be the impact of these findings on clinical practice? (3:04)
6. What are the hot topics and latest research you are looking forward to exploring in EoE? (3:34)

Disclosures: Arjan Bredenoord discloses consulting for AstraZeneca, Dr Falk, Laborie, Medtronic, Regeneron Pharmaceuticals, Inc., and Alimentiv; and receiving grant/ research support from Bayer, Nutricia and SST.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed as a highlight of UEG Week 2022.